Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 234 (3), 317-23

The Cost-Effectiveness of Treating Hypertension in Elderly People--An Analysis of the Swedish Trial in Old Patients With Hypertension (STOP Hypertension)

Affiliations
Clinical Trial

The Cost-Effectiveness of Treating Hypertension in Elderly People--An Analysis of the Swedish Trial in Old Patients With Hypertension (STOP Hypertension)

M Johannesson et al. J Intern Med.

Abstract

Objectives: The aim of this study was to estimate the cost-effectiveness of antihypertensive treatment in elderly people based on the results of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension).

Design: The STOP Hypertension study was a randomized trial comparing active antihypertensive treatment with a placebo. The risk of stroke, cardiovascular disease and total mortality was significantly reduced in the actively treated group compared to placebo.

Setting: One hundred and sixteen primary health care centres in Sweden.

Subjects: A total of 1627 hypertensive patients aged 70-84. No patient was lost to follow-up.

Interventions: Antihypertensive treatment with beta blockers and diuretics for a mean follow-up of 25 months.

Main outcome measure: The cost-effectiveness ratio estimated as the net cost (the treatment cost minus saved costs of reduced cardiovascular morbidity) divided by the number of life-years gained (the increase in life expectancy from treatment).

Results: The cost per life-year gained was estimated as SEK 5000 for men and SEK 15,000 for women ($1 = SEK 6; 1 pound = SEK 10). The cost per life-year gained did not exceed SEK 100,000 in any of the sensitivity analyses.

Conclusions: It is concluded that treatment of elderly hypertensive patients with beta blockers and/or diuretics is cost-effective according to the results of the STOP Hypertension study.

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

  • Pharmacoeconomics and Aging
    S Bustacchini et al. Drugs Aging 26 Suppl 1, 75-87. PMID 20136171. - Review
    The aging of the general population in industrialized countries has brought to public attention the increasing incidence of age-related clinical conditions, because the l …
  • Cost-effectiveness Analysis of Guidelines for Antihypertensive Care in Finland
    N Booth et al. BMC Health Serv Res 7, 172. PMID 17958883.
    The ACCG scenario is likely to reduce costs and increase life-years compared to the PCP scenario in many subgroups. If the estimated trade-offs between the subgroups in t …
  • Cost-effectiveness in Preventive Cardiology
    WS Weintraub. Curr Treat Options Cardiovasc Med 6 (4), 279-290. PMID 15212723.
    Cardiovascular disease remains a serious medical problem, which can be associated with death and disability on one hand, and considerable resource utilization on the othe …
  • Economics of Antihypertensive Therapy in the Elderly
    EC Dunn et al. Drugs Aging 18 (7), 515-25. PMID 11482745. - Review
    Because of the high incidence of morbidity and mortality associated with hypertension in the elderly, the treatment of hypertension in this patient group must involve con …
  • Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults
    AD Brown et al. Pharmacoeconomics 14 (1), 27-48. PMID 10182193. - Review
    Although risk-factor modification has gained wide acceptance as an effective approach to the prevention of coronary heart disease (CHD), health planners, physicians and p …
See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback